37 / 38
Where can we use it? Potential algorithm
Good risk
Intermediate or Poor
risk
First Line
Options
Sunitinib
Pazopanib
Tivozanib
Nivolumab + Ipilimumab
Cabozantinib
Axitinib + Avelumab*
Axitinib + Pembrolizumab**
Second Line
Post-TKI
Nivolumab
Cabozantinib
Axitinib
Post-IO
Any Tki
(Tivozanib)
* Pending OS PDL1+
** Data not presented